linjc16/ctgov huggingface dataset:
Comparison of Magnetic Resonance Techniques for the Measurement of Cerebral Blood Perfusion

Study Overview
=================
Brief Summary
-----------------
In this project, we aim at implementing a te-ASL sequence and to compare it to two reference ASL sequences with a fixed PLD on healthy individuals. On the one hand, the te-ASL sequence will be compared against a 3D pCASL with a PLD of 1800 ms, as the current reference according the Consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. On the other, as the implemented te-ASL sequence will have a 2D readout, it will also be compared to a 2D pCASL ASL sequence with the same PLD, in order to be able to disentangle differences due to the dynamic PLD scheme from those arising from the different read-out schemes.

Official Title
-----------------
Comparison of Magnetic Resonance Techniques for the Measurement of Cerebral Blood Perfusion

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To sign the study informed consent form approved by the corresponding authorities. Healthy men and women (older than 18 years old). Exclusion Criteria: Inability or unwillingness to give written informed consent or communicate with the study staff or illiteracy. Any contraindication to perform brain MRI procedure (e.g. pacemaker, MRI-incompatible aneurysm clips).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ASL perfusion MRI data | Quantification of cerebral blood flow | Through study completion, an average of 1 year |
HPV Integration Testing for Cervical Cancer Screening

Study Overview
=================
Brief Summary
-----------------
The primary objective is to determine the sensitivity and specificity of the HPV Integration-based cervical screening for detection of high-grade cervical intraepithelial neoplasia (CIN), using colposcopic inspection as the reference method. Lesions will be confirmed as malignant or CIN by colposcopic inspection and histopathologic examination.

Official Title
-----------------
HPV（Human Papillomavirus） Integration Testing for Cervical Cancer Screening

Conditions
-----------------
Cervical Cancer, Cervical Intraepithelial Neoplasia

Intervention / Treatment
-----------------
* Procedure: TCT，HPV，colposcopic inspection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 30-65 years old Attending the China population-based organised cervical screening program Exclusion Criteria: Not providing informed consent previously confirmed CIN, cervical cancer, or other malignancies previous therapeutic procedure to cervix pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects will be women, 30-65 years of age<br>Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment. | Procedure: TCT，HPV，colposcopic inspection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the sensitivity and specificity of the HPV Integration-based cervical screening for detection of high-grade cervical intraepithelial neoplasia (CIN)with comparison to HPV testing or TCT |  | 14 Months |
Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass

Study Overview
=================
Brief Summary
-----------------
Target controlled infusion with remifentanil is widely used during cardiac surgery, wich is performed using the Minto model. It was derived from patients undergoing general surgery. However, pharmacokinetics of remifentanil can be changed during cardiopulmonary bypass. The investigators tested whether Minto model for target controlled infusion produces constant plasma remifentanil concentration during the cardiac surgery.

Official Title
-----------------
Performance of the Minto Model in Effect Site Mode for Target Controlled Infusion of Remifentanil During Cardiopulmonary Bypass

Conditions
-----------------
Anesthetics, Intravenous, Pharmacology, Anesthetics, Cardiopulmonary Bypass

Intervention / Treatment
-----------------
* Drug: Remiva
* Drug: Ultiva


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with the ASA class I III undergoing elective cardiac surgery using cardiopulmonary bypass Exclusion Criteria: Patients not using target controlled infusion during the operation Patients with drug/substance abuse Patients using analgesics before this study starts Pregnant women Patients who rejected study participation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Remiva<br>This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company. | Drug: Remiva<br>* Target controlled infusion of remifentanil (generic drug, Remiva™)<br>* Other names: generic drug of remifentanil, Remiva™;|
| Active Comparator: Ultiva<br>This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company. | Drug: Ultiva<br>* Target controlled infusion of remifentanil (brand-named drug, Ultiva™)<br>* Other names: brand-named drug of remifentanil, Ultiva™;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Median prediction error |  | during CPB | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes of measured total remifentanil concentration |  | 1 hour after anesthesia induction, 30/60/90 min after the beginning of cardiopulmonary bypass, 1 hour after the end of cardiopulmonary bypass | 
| Median absolute prediction error |  | during CPB | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
remifentanil
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.

Official Title
-----------------
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Conditions
-----------------
ADHD

Intervention / Treatment
-----------------
* Drug: Focalin XR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV diagnosis of ADHD Males and females aged 6-12 Exclusion Criteria: Inability to understand or follow instructions Is pregnant Diagnosis of tic disorder History of seizure disorder

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Focalin XR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in attention and deportment measured at 2 hours post-dose |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onset of effect at 0.5, 1, 2, 3, 4, 6, 8, 10, 11, and 12 hours post-dose |  |  | 
| Parent's assessment of patient behavior across all treatment periods as measured by the change from baseline |  |  | 
| Safety and tolerability of two doses of dexmethylphenidate compared to two doses of an approved, long-acting, marketed medication for ADHD and placebo in children ages 6-12 diagnosed with ADHD. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADHD, children
Mild To Moderate Erectile Dysfunction Study

Study Overview
=================
Brief Summary
-----------------
Safety/Efficacy of 100-mg Viagra at 8 hours post dose in men with mild to moderate erectile dysfunction

Official Title
-----------------
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose

Conditions
-----------------
Impotence

Intervention / Treatment
-----------------
* Drug: Viagra (Sildenafil Citrate) 100 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men 18-70 years of age Documented clinical diagnosis of erectile dysfunction of at least 3 months duration. Exclusion Criteria: Subjects with penile implants Subjects with a known history of retinitis pigmentosa. Subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent CYP3A4 inhibitor ritonavir.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Viagra (Sildenafil Citrate) 100 mg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 8 hrs after a dose of Viagra. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 12 hrs after a dose of Viagra. Other questionnaires such as SEP, IIEF. |  |  |
The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

Study Overview
=================
Brief Summary
-----------------
This study investigates the association between the microvascular resistance at the time of primary percutaneous intervention, with microvascular obstruction on CMR and blood markers of myocardial damage.

Official Title
-----------------
The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

Conditions
-----------------
STEMI

Intervention / Treatment
-----------------
* Procedure: Index of microvascular resistance
* Other: Cardiac magnetic resonance
* Other: Blood markers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old Cardiac symptoms of > 20 mins chest pain or equivalent. ECG criteria consistent with STEMI (STEMI) Proceeding with percutaneous angioplasty Assent/ consent to the study Exclusion Criteria: Known allergy to adenosine or gadolinium Chronic atrial fibrillation Renal impairment with eGFR <30 Contraindication to angiography Contraindication to CMR (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner) Cardiogenic shock Patients with special communication needs or altered consciousness. Patients who do not give assent/consent to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| STEMI patients<br>Consecutive patients presenting through the PPCI service | Procedure: Index of microvascular resistance<br> <br> Other: Cardiac magnetic resonance<br> <br> Other: Blood markers<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microvascular obstruction | Microvascular obstruction as a percentage of the left ventricle at 2-4 days. | DAy 2-4 |
Use of IMSI in Poor Responders to IVF

Study Overview
=================
Brief Summary
-----------------
This is a pilot study which aims to determine the role of IMSI in poor responders.

Detailed Description
-----------------
This is a pilot study which aims to determine the role of IMSI over ICSI in poor responders to IVF, without a background of teratozoospermia.

Official Title
-----------------
Use of Intra-Cytoplasmic Morphologically Selected Sperm Injection (IMSI) in Poor Responders to In Vitro Fertilization (IVF): a Prospective, Double-blind, Randomized, Controlled Trial

Conditions
-----------------
Female Infertility

Intervention / Treatment
-----------------
* Procedure: Intra-cytoplasmic Sperm Injection
* Procedure: Intra-cytoplasmic Morphologically-selected Sperm Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: poor ovarian response Exclusion Criteria: body mass index (BMI) ≥ 30 kg/m2 presence of endocrinopathies (e.g., diabetes, hyperprolactinemia, hypothyroidism) altered karyotype or documented genetic defects in one or both partners history of chronic, autoimmune or metabolic diseases altered meiosis in testicular biopsy or altered sperm-FISH teratozoospermia participation, simultaneously or within the previous 6 months, in another clinical trial with medication

Ages Eligible for Study
-----------------
Minimum Age: 37 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI) | Procedure: Intra-cytoplasmic Morphologically-selected Sperm Injection<br>* Selection of sperm at 6000x for sperm injection<br>|
| Active Comparator: Control<br>Intracytoplasmic sperm injection (ICSI) | Procedure: Intra-cytoplasmic Sperm Injection<br>* Selection of sperm at 400x for sperm injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | Percentage of patients presenting with presence of an intrauterine gestational sac with embryonic cardiac activity display, evaluated by ultrasound, per cycle initiated | Four to six weeks after embryo transfer | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of embryos obtained | Total number of embryos obtained | Two days after egg retrieval | 
| Percentage of cycles with embryo transfer | Number of cycles reaching embryo transfer per cycle initiated | Two days after egg retrieval | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
POR, IMSI
Study of Quantification of Hyperpronation

Study Overview
=================
Brief Summary
-----------------
Hyperpronation is af frequent cause of excessive load in foot and crus. Pain and limited functional ability cause problems with work-related activities, sport activities and leisure activities. There are only few studies of the frequency of pain related to hyperpronation in foot and the effect of exercises. Medics and physiotherapists need sufficient evidence-based knowledge to treat these patients correctly. Therefore, the investigators want to study the effect of exercises and inner soles for treatment of patients with chronic pain and hyperpronation of foot.

Official Title
-----------------
Study of Quantification of Hyperpronation

Conditions
-----------------
Foot Pain Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hyperpronation of foot Consent of information Exclusion Criteria: Normal gait Lack of consent of information Unable to speak and read Danish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 68 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain, Foot
Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and TypicalARDS Patients

Study Overview
=================
Brief Summary
-----------------
Covid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia may differ from typical Acute Respiratory Distress Syndrome (ARDS) due to maldistribution of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different, which requires different interventions than typical ARDS. The investigators will assess whether extravascular lung water index and permeability of the alveolar capillary differs from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.

Official Title
-----------------
Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and TypicalARDS Patients

Conditions
-----------------
Respiratory Distress Syndrome, Adult, Ventilation Perfusion Mismatch, Pulmonary Edema, Covid19

Intervention / Treatment
-----------------
* Device: Extravascular Lung Water Index
* Device: Pulmonary Vascular Permeability Index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ARDS defined by Berlin Criteria longer than 24 hours Undergoing mechanical ventilation Noradrenaline demand >0.1 mcg/kg/min Exclusion Criteria: Not meeting ARDS criteria Noninvasive mechanical ventilation ARDS resolved shorter than 24 hours Shock resolved

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Typical ARDS<br>ARDS due to non Covid19 causes | Device: Extravascular Lung Water Index<br>* Measurement of the EVLWI<br>Device: Pulmonary Vascular Permeability Index<br>* Measurement of the PVPI<br>|
| C-ARDS<br>ARDS due to Covid19 | Device: Extravascular Lung Water Index<br>* Measurement of the EVLWI<br>Device: Pulmonary Vascular Permeability Index<br>* Measurement of the PVPI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extravascular Lung Water Index | The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg) | 1 day | 
| Pulmonary vascular permeability index | Integrity of the alveolocapillary barrier measured by transpulmonary thermodilution | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ards, covid19
Simulation of Adenosine Push Methods for Treatment of SVT Using Agitated Saline Visualized by Ultrasound

Study Overview
=================
Brief Summary
-----------------
Supraventricular tachycardia (SVT) is an abnormally fast heart rhythm arising from improper electrical activity in the upper part of the heart. SVT is commonly treated with adenosine using three different IV administration techniques. However, it is not well known which of these three techniques is the quickest or most likely to reach the heart in order to stop SVT. This study will simulate each of those techniques in an investigator-blinded procedure. Intravenous agitated saline, used as a surrogate for a dose of adenosine, will be administered to healthy volunteers using all three techniques and monitored using bedside ultrasound to observe their efficacy and speed in reaching the right side of the heart.

Official Title
-----------------
Simulation of Adenosine Push Methods for Treatment of SVT Using Agitated Saline Visualized by Ultrasound

Conditions
-----------------
Supraventricular Tachycardia

Intervention / Treatment
-----------------
* Other: Agitated saline push


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers aged 18 years and older Able to understand and provide signed consent for the study Must be healthy; not being actively treated for any condition that requires active medical intervention or monitoring to avert serious danger to the participant's health or well-being, as evaluated by study investigator Exclusion Criteria: Non-English speaker Those with contraindications to peripheral IV placement, such as infection or other contraindication noted from evaluation by study investigator Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: This is a simulation study in which all participants receive a dose of agitated saline through an IV using three different administration methods.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Simulation arm<br>All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized. | Other: Agitated saline push<br>* Push of agitated saline to simulate adenosine used for supraventricular tachycardia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to ultrasound visualization of agitated saline in the right heart | Time from IV push to ultrasound visualization of agitated saline in the right heart | <5 seconds |